Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 1;20(2):273-286.
doi: 10.1093/biostatistics/kxx069.

Estimation of clinical trial success rates and related parameters

Chi Heem Wong  1 , Kien Wei Siah  1 , Andrew W Lo  2
Affiliations

Estimation of clinical trial success rates and related parameters

Chi Heem Wong et al. Biostatistics. .

Erratum in

Abstract

Previous estimates of drug development success rates rely on relatively small samples from databases curated by the pharmaceutical industry and are subject to potential selection biases. Using a sample of 406 038 entries of clinical trial data for over 21 143 compounds from January 1, 2000 to October 31, 2015, we estimate aggregate clinical trial success rates and durations. We also compute disaggregated estimates across several trial features including disease type, clinical phase, industry or academic sponsor, biomarker presence, lead indication status, and time. In several cases, our results differ significantly in detail from widely cited statistics. For example, oncology has a 3.4% success rate in our sample vs. 5.1% in prior studies. However, after declining to 1.7% in 2012, this rate has improved to 2.5% and 8.3% in 2014 and 2015, respectively. In addition, trials that use biomarkers in patient-selection have higher overall success probabilities than trials without biomarkers.

Keywords: Clinical phase transition probabilities; Clinical trial statistics; Probabilities of success.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The POS over the period of January 1, 2005, to October 31, 2015, computed using a 3-year rolling window from January 1 in year formula image to December 31 in year formula image, with the exception of the last window, which terminates on October 31, 2015. This POS is computed using the phase-by-phase method, our adaptation of Hay and others (2014)’ methodology, which reports the proportion of phase transitions that advances to the next phase. The algorithm from Figure S5 in the Supplementary Material is not used, as it would overestimate the phase success if applied to a short window. The result for 2015 has to be treated with caution, as boundary effects increase the success rates artificially.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abrantes-Metz R. M., Adams C. and Metz A. D. (2005). Pharmaceutical development phases: a duration analysis. Journal of Pharmaceutical Finance, Economics and Policy 14, 19–42.
    1. Danzon P. M., Nicholson S. and Pereira N. S. (2005). Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances. Journal of Health Economics 24, 317–339. - PubMed
    1. DiMasi J. A., Feldman L., Seckler A. and Wilson A. (2010). Trends in risks associated with new drug development: success rates for investigational drugs. Clinical Pharmacology and Therapeutics 87, 272–277. - PubMed
    1. Hay M., Thomas D. W., Craighead J. L., Economides C. and Rosenthal J. (2014). Clinical development success rates for investigational drugs. Nature Biotechnology 32, 40–51. - PubMed
    1. Malec P. and Schienle M. (2014). Nonparametric kernel density estimation near the boundary. Computational Statistics & Data Analysis 72, 57–76.

Publication types